BHCBullishBausch Health Q3 results and guidance raisenews
Medium materiality6/10
This $8 pharma stock is up 52%and still trades at 1.6x earnings
Nov 20, 2026, 9:34 AM EST1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
The guidance raise and stronger-than-expected Q3 results indicate improving revenue and EBITDA generation, which supports faster debt paydown and better cash flow; the magnitude of sustainable margin improvement and impact on leverage depend on coming quarters and sales durability.
AI summary
What happened, with direct paths to the underlying reporting
Bausch Health reported Q3 revenue, EPS and adjusted EBITDA above consensus and raised full-year revenue and adjusted EBITDA guidance while reducing net debt.
Bausch Health reported third-quarter revenue of $2.941 billion.
Adjusted EPS for the quarter was $1.77, topping the $1.27 consensus.
Adjusted EBITDA for the quarter was $1.305 billion, up 32% and the first quarter above $1 billion.
Management raised its full-year outlook to revenue of $10.975 billion to $11.175 billion and adjusted EBITDA of $4.315 billion to $4.415 billion.
Net debt has fallen by more than $1 billion since the start of 2026 to $13.132 billion.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event